2Gary Walsh. Biopharmaceuticals: Biochemistry and biotechnology[M]. Second Edition(2003). John Wiley & Sons Ltd, ISBN0-470-84326-8.
3Walsh, G. Biopharmaceutic benchmarks-2003[J]. Nat. Biotechnol. 2003; 2l(2):870-878.
4Bibby, K., Davis, J., Jones, C.Biopharmaceuticals - Moving to Centre Stage[M].BioPeople North, American Biotechnology Industry and Suppliers' Guide.2003:3-11.
5Beijing Pharma and Biotech Center, Annual report for development of Beijing Pharma & Biotech industry: 2005[R]. China Science Press,2005:78-106.
6Hu, X. W., Ma, Q. J., Zhang, S. Y. Biopharmaceuticals in China[J]. Biotechnol,2006,1:12 I5 - 1224.
7Schofleld J. R., Robinson W.A., Murphy J. R., et al. Low doses of Interferon-or are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia[J]. Ann Inter Med, 1994,121(10):736-743.
9Natarajan A, Xiong CY, Albrecht H,et al. Characterization of site- specific ScFv PEGylation for tumor-targeting pharmaceuticals[J]. Bioconjugate Chem, 2005,16(1):113-121.
10Nieri P., Donadia E.,Rossi S.,et al. Antibodies for therapeutic uses and the evolution of biotechniques[J]. Current Medicinal Chemistry,2009,16(6):753-779.
